[Deep brain stimulation in the management of Parkinson's disease].
Deep brain stimulation (DBS) is a neurosurgical treatment of Parkinson's disease and other movement disorders. This surgical technique is applied to three brain targets: the ventral intermediate nucleus of the thalamus (Vim), the globus pallidus internus (Gpi) and the subthalamic nucleus (STN). Vim DBS improves contralateral parkinsonian tremor. STN and GPi DBS improve contralateral bradykinesia, rigidity, parkinsonian tremor and also levodopa-induced dyskinesia. There is little comparative data between bilateral STN and bilateral GPi procedures but the improvement with bilateral STN DBS seems more pronounced than with bilateral GPi DBS. Moreover, only STN BDS allows a significant decrease of antiparkinsonian medication. The other advantage of STN over GPi DBS is the lower consumption of current. The DBS procedure contrary to ablative surgery has the unique advantage of reversibility and adjustability over time. Patients with no behavioral, mood and cognitive impairments benefit the most from bilateral STN DBS. The stimulation-induced adverse effects related to DBS are reversible and adjustable. More specific adverse effects related do hardware are: disconnection, lead breaking, erosion or infection. The disadvantage of DBS is a relatively high cost. The setting of stimulation parameters to achieve the best clinical result may be very time-consuming. Most authors agree that DBS is a safer and more favorable procedure than ablative surgery.
Zabek
Mirosław
M
Klinika Neurochirurgii, CMKP, Wojewódzki Szpital Bródnowski w Warszawie, Warszawa.
Sobstyl
Michał
M
D000978:Antiparkinson Agents / Q000008:administration & dosage; D046690:Deep Brain Stimulation / Q000191:economics / Q000295:instrumentation; D004868:Equipment Failure; D005917:Globus Pallidus / Q000503:physiopathology; D006801:Humans; D010300:Parkinson Disease / Q000628:therapy*; D020531:Subthalamic Nucleus / Q000503:physiopathology; D020651:Ventral Thalamic Nuclei / Q000503:physiopathology
D000978:Antiparkinson Agents